Tech Company Financing Transactions
Mersana Therapeutics Funding Round
Mersana Therapeutics, operating out of Cambridge, secured $10 million in investment from F-Prime Capital and ProQuest Investments.
Transaction Overview
Company Name
Announced On
6/30/2007
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
F-Prime Capital (Jason Rhodes)
ProQuest Investments (Joyce Tsang)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
840 Memorial Dr.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anna Protopapas
Chief Medical Officer
Dirk Huebner
Chief Scientific Officer
Timothy Lowinger
VP - Bus. Development
Eva Jack
VP - Finance
Brian DeSchuytner
VP - Manufacturing
Michael Kaufman
Browse more venture capital transactions:
Prev: 6/30/2007: CorEdge Networks venture capital transaction
Next: 6/30/2007: Grid Net venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs